It has therefore been proposed that PTEN status could be used to distinguish between indolent and progressive prostate cancer and accordingly, PTEN is a component of several biomarker signatures which appear to have some power to identify aggressive disease [11,12,13,14,15,16,17,18,19]. The gene discussed is PTEN; the disease is prostate cancer.